Author:
Borgeraas Heidi,Hjelmesæth Jøran,Birkeland Kåre Inge,Fatima Farhat,Grimnes John Olav,Gulseth Hanne L,Halvorsen Erling,Hertel Jens Kristoffer,Hillestad Tor Olav Widerøe,Johnson Line Kristin,Karlsen Tor-Ivar,Kolotkin Ronette L,Kvan Nils Petter,Lindberg Morten,Lorentzen Jolanta,Nordstrand Njord,Sandbu Rune,Seeberg Kathrine Aagelen,Seip Birgitte,Svanevik Marius,Valderhaug Tone Gretland,Hofsø Dag
Abstract
IntroductionBariatric surgery is increasingly recognised as an effective treatment option for subjects with type 2 diabetes and obesity; however, there is no conclusive evidence on the superiority of Roux-en-Y gastric bypass or sleeve gastrectomy. The Oseberg study was designed to compare the effects of gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function.Methods and analysisSingle-centre, randomised, triple-blinded, two-armed superiority trial carried out at the Morbid Obesity Centre at Vestfold Hospital Trust in Norway. Eligible patients with type 2 diabetes and obesity were randomly allocated in a 1:1 ratio to either gastric bypass or sleeve gastrectomy. The primary outcome measures are (1) the proportion of participants with complete remission of type 2 diabetes (HbA1c≤6.0% in the absence of blood glucose-lowering pharmacologic therapy) and (2) β-cell function expressed by the disposition index (calculated using the frequently sampled intravenous glucose tolerance test with minimal model analysis) 1 year after surgery.Ethics and disseminationThe protocol of the current study was reviewed and approved by the regional ethics committee on 12 September 2012 (ref: 2012/1427/REK sør-øst B). The results will be disseminated to academic and health professional audiences and the public via publications in international peer-reviewed journals and conferences. Participants will receive a summary of the main findings.Trial registration numberNCT01778738;Pre-results.
Funder
THe Morbid Obesity Centre at Vestfold Hospital Trust